| 臺大學術典藏 |
2021-08-12T04:01:22Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; YANG SHIH-HUNG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-10T03:53:01Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-10T03:53:00Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-03-05T06:07:25Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; MING-CHU CHANG; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-23T08:26:14Z |
The Epidemiology of Gastric Cancers in the Era of Helicobacter pylori Eradication: A nationwide cancer registry-based study in Taiwan
|
Chang J.S.;Sung-Hsin Kuo;Chu P.-Y.;Shan Y.-S.;Tsai C.-R.;Tsai H.-J.;Chen L.-T.; Chang J.S.; SUNG-HSIN KUO; Chu P.-Y.; Shan Y.-S.; Tsai C.-R.; Tsai H.-J.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.;Tsai K.K.;Hsiao C.-F.;Yang S.-H.;Hsiao H.-H.;Shen W.-C.;Chiun Hsu;Lin Y.-L.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; Yang S.-H.; Hsiao H.-H.; Shen W.-C.; Chiun Hsu; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.;Chou W.-C.;Hsiao C.-F.;Jiang S.S.;Tsai H.-J.;Liu Y.-C.;Chiun Hsu;Shan Y.-S.;Hung Y.-P.;Hsich C.-H.;Chiu C.-H.;Liu T.-C.;Cho S.-F.;Liu T.-W.;Chao Y.; Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; Chiun Hsu; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.;Chen M.-H.;Yang S.-H.;Chiun Hsu;Yen C.-J.;Tsou H.-H.;Su Y.-Y.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Chen M.-H.; Yang S.-H.; Chiun Hsu; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:35Z |
Management of gastric cancer in Asia: Resource-stratified guidelines
|
Shen L.;Shan Y.-S.;Hu H.-M.;Price T.J.;Sirohi B.;Kun-Huei Yeh;Yang Y.-H.;Sano T.;Yang H.-K.;Zhang X.;Park S.R.;Fujii M.;Kang Y.-K.;Chen L.-T.; Shen L.; Shan Y.-S.; Hu H.-M.; Price T.J.; Sirohi B.; KUN-HUEI YEH; Yang Y.-H.; Sano T.; Yang H.-K.; Zhang X.; Park S.R.; Fujii M.; Kang Y.-K.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-15T03:47:00Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; HSIU-PO WANG; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 國立成功大學 |
2021 |
Comparing the clinicopathological characteristics of combined hepatocellular–cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification
|
Yen, C.-C.;Yen, C.-J.;Shan, Y.-S.;Lin, Y.-J.;Liu, I.-T.;Huang, Huang H.-Y.;Yeh, M.M.;Chan, S.-H.;Tsai, H.-W. |
| 國立成功大學 |
2021 |
No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol
|
Shan, Y.-S.;Chen, L.-T.;Wu, C.-H.;Chang, Y.-F.;Lee, C.-T.;Chiang, N.-J.;Chao, Y.-J.;Yen, C.-J.;Tsai, H.-J.;Huang, Huang H.-E.;Tsai, C.-R.;Weng, Y.-L.;Yang, H.-C.;Liu, H.-C.;Chang, J.S. |
| 國立成功大學 |
2021 |
High expression of kr�ppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial
|
Pen, S.-L.;Shan, Y.-S.;Hsiao, C.-F.;Liu, T.-W.;Chen, J.-S.;Ho, C.-L.;Chou, W.-C.;Hsieh, R.-K.;Chen, L.-T.;Ch'ang, H.-J. |
| 國立成功大學 |
2021 |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu, Hu H.-M.;Tsai, H.-J.;Ku, H.-Y.;Lo, S.-S.;Shan, Y.-S.;Chang, H.-C.;Chao, Y.;Chen, J.-S.;Chen, S.-C.;Chiang, Chiang C.-J.;Li, A.F.-Y.;Wang, H.-P.;Wang, T.-E.;Bai, L.-Y.;Wu, M.-S.;Chen, L.-T.;Liu, T.-W.;Yang, Yang Y.-H. |
| 國立成功大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, T.-J.;Su, Y.-Y.;Yang, S.-H.;Li, C.-P.;Bai, L.-Y.;Chiang, N.-J.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
| 國立成功大學 |
2021 |
Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer
|
Wang, C.-Y.;Chao, Y.-J.;Chen, Y.-L.;Wang, T.-W.;Phan, N.N.;Hsu, Hsu H.-P.;Shan, Y.-S.;Lai, M.-D. |
| 國立成功大學 |
2021 |
A multi-mode Wnt- and stemness-regulatory module dictated by FOXM1 and ASPM isoform I in gastric cancer
|
Hsu, C.-C.;Liao, W.-Y.;Chang, K.-Y.;Chan, T.-S.;Huang, P.-J.;Chiang, Chiang C.-T.;Shan, Y.-S.;Cheng, L.-H.;Liao, T.-Y.;Tsai, K.K. |
| 國立成功大學 |
2021 |
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation
|
Chang, T.-M.;Chu, P.-Y.;Hung, W.-C.;Shan, Y.-S.;Lin, H.-Y.;Huang, K.-W.;Chang, J.S.;Chen, L.-T.;Tsai, H.-J. |
| 國立成功大學 |
2021 |
The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors – A Single-Center Experience
|
Tsai, H.-J.;Hsiao, C.-F.;Chang, J.S.;Chen, L.-T.;Chao, Y.-J.;Yen, C.-J.;Shan, Y.-S. |
| 國立成功大學 |
2021 |
Development of possible next line of systemic therapies for gemcitabine-resistant biliary tract cancers: A perspective from clinical trials
|
Chiang, N.-J.;Chen, L.-T.;Shan, Y.-S.;Yeh, C.-N.;Chen, M.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; CHIH-HUNG HSU; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T.; Ch'Ang H.-J. ;Lin Y.-L. ;Wang H.-P. ;Chiu Y.-F. ;Chang M.-C. ;Chih-Hung Hsu ;Tien Y.-W. ;Chen J.-S. ;Hsieh R.-K. ;Lin P.-W. ;Shan Y.-S. ;Cheng A.-L. ;Chang J.-Y. ;Whang-Peng J. ;Hwang T.-L. ;Chen L.-T. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chen L.-T.; Huang S.-F.; Chen J.-S.; Tsou H.-H.; Shen Y.-Y.; Chao Y.; Chen M.-H.; Yeh T.-S.; Shan Y.-S.; Chiun Hsu; Chiang N.-J.; Chiang N.-J.;Chiun Hsu;Chen J.-S.;Tsou H.-H.;Shen Y.-Y.;Chao Y.;Chen M.-H.;Yeh T.-S.;Shan Y.-S.;Huang S.-F.;Chen L.-T. |
| 臺大學術典藏 |
2020-03-07T06:48:18Z |
Krüppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma
|
Ch'Ang H.-J.; Yu W.C.Y.; Tsai K.K.C.; Lin C.-Y.; Hsu C.-F.; Shan Y.-S.; Chu P.-Y.; Peng S.-L.; TSUI-LIEN MAO; Chang V.H.S. |
| 臺大學術典藏 |
2020-03-05T12:32:51Z |
Kr?ppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma
|
Chang V.H.S.; Chu P.-Y.; Peng S.-L.; TSUI-LIEN MAO; Shan Y.-S.; Hsu C.-F.; Lin C.-Y.; Tsai K.K.C.; Yu W.C.Y.; Ch'Ang H.-J. |
| 臺大學術典藏 |
2020-02-20T06:53:13Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T.; Shan Y.-S.; Cheng A.-L.; Lin P.-W.; Chen J.-S.; Hsieh R.-K.; YU-WEN TIEN; Ch'Ang H.-J.;Lin Y.-L.;Wang H.-P.;Chiu Y.-F.;Chang M.-C.;Hsu C.-H.;Yu-Wen Tien;Chen J.-S.;Hsieh R.-K.;Lin P.-W.;Shan Y.-S.;Cheng A.-L.;Chang J.-Y.;Whang-Peng J.;Hwang T.-L.;Chen L.-T.; Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H. |
